2024-515310-40-01招募中2 期
Multicentric non-randomized phase II of pembrolizumab in combination with etoposide-cisplatin-based chemotherapy in first-line small cell ovarian carcinoma of hypercalcemic type
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 27
- 试验地点
- 13
- 主要终点
- Complete response rate is documented using RECIST 1.1
研究概览
简要总结
To estimate the complete response rate after perioperative treatment by chemotherapy and immunotherapy, using the RECIST 1.1
入排标准
- 年龄范围
- 0 years 至 65+ years（65+ Years, 0-17 Years, 18-64 Years）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patient who are at least 12 years of age on the day of signing informed consent with previously untreated, pathologically confirmed small cell carcinoma of the ovary. Patients could be included after one cycle of chemotherapy but have to start treatment within 4 weeks after the first cycle of chemotherapy. They will start the scheme at cycle
- •Stage FIGO I to IV classification
- •Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1
- •Have adequate organ function: • Adequate marrow function White blood cell (WBC) >2000/mm3 (stable off any growth factor within 4 weeks of first study drug administration) Neutrophils >1500/ mm3 (stable off any growth factor within 4 weeks of first study drug administration) Platelets > 100 × 103/mm3 (transfusion to achieve this level is not permitted within 2 weeks of first study drug administration) Haemoglobin > 9 g/dL (transfusion to achieve this level is not permitted within 2 weeks of first study drug administration) • Adequate other organ functions ALT and AST < 3× institutional ULN Total bilirubin < 1.5× institutional ULN (except Gilbert Syndrome: < 3.0 mg/dL) Normal thyroid function, subclinical hypothyroidism (thyroid-stimulating hormone [TSH] < 10 mIU/mL) or have controlled hypothyroidism on appropriate thyroid supplementation Left ventricular ejection fraction (LVEF) > 55 % measured by ECHO (preferred) or MUGA scans Serum creatinine < 2× ULN or creatinine clearance (CrCl) > 60 mL/min (measured using the Cockcroft-Gault formula below):
- •The participant (or legally acceptable representative if applicable) provides written informed consent for the trial, prior to any study-specific procedure. The participant may also provide consent for Future Biomedical Research. However, participant may participate in the main trial without participating in Future Biomedical Research.
- •Covered by a medical insurance.
- •Stated willingness to comply with all study procedures and availability for the duration of the study.
- •Women of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to treatment allocation.
- •For females of reproductive potential: use of highly effective contraception throughout the study period up to 120 days after the last dose of pembrolizumab and 180 days following the end of chemoradiotherapy (if applicable).
排除标准
- •Prior therapy for the disease with chemotherapy and/or an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137).
- •Patients who have an active autoimmune disease that has required systemic treatment in past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency) is not considered a form of systemic treatment and is allowed.
- •Patients who have a history of (non-infectious) pneumonitis/ interstitial lung disease that required steroids or has current pneumonitis / interstitial lung disease that requires steroids.
- •Has an active infection requiring systemic therapy.
- •Has a known history of human immunodeficiency virus (HIV) infection. HIV testing is not required unless mandated by local health authority.
- •Has a history of hepatitis B (defined as hepatitis B surface antigen [HBsAg] reactive) or active hepatitis C virus (defined as HCV RNA [qualitative] is detected) infection.
- •Has a known history of active tuberculosis (TB; Bacillus tuberculosis)
- •Has a history or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the participant's participation for the full duration of the study, or is not in the best interest of the participant to participate, in the opinion of the treating investigator.
- •Has a known psychiatric or substance abuse disorder that would interfere with cooperating with the requirements of the study.
- •Breastfeeding women.
- •Participation in another clinical study with an investigational product 30 days prior and during the treatment course, and 30 days after end of treatment.
- •Patients who have received a live vaccine within 30 days prior to the first dose of study drug. Examples of live vaccines include, but are not limited to, the following: measles, mumps, rubella, varicella/zoster (chicken pox), yellow fever, rabies, Bacillus Calmette–Guérin (BCG), and typhoid vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed; however, intranasal influenza vaccines (e.g., FluMist®) are live attenuated vaccines and are not allowed. Inactivated rabies vaccines are allowed.
- •Patients who have had an allogenic tissue/solid organ transplant.
- •Patient who has received more than one cycle of platinum-based chemotherapy, or any prior systemic anti-cancer therapy including investigational agents for the SCCOHT. (Patients could be included after one cycle of platinum-based therapy).
- •Patients who have a known diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg prednisone daily or equivalent) or any other form of immunosuppressive therapy within 7 days prior the first dose of study drug.
- •Patients who have a known additional malignancy that is progressing or has required active treatment within the past 5 years. Note: Participants with basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, or carcinoma in situ (e.g., breast carcinoma, cervical cancer in situ) that have undergone potentially curative therapy are not excluded.
- •Patients who have a contraindication to any component of cisplatin, adriamycine, vepeside and cyclophosphamide. Note: Investigators must use the local label for contraindications, prohibited medications, and precautions for use.
- •Patients who have severe hypersensitivity (Grade 3 or higher) to pembrolizumab and/or any of its excipients (refer to the IB for a list of excipients).
- •Patients who have a known severe hypersensitivity (Grade 3 or higher) to any of the study chemotherapy agents and/or to any of their excipients (refer to the approved product label(s) for a list of excipients).
结局指标
主要结局
Complete response rate is documented using RECIST 1.1
Complete response rate is documented using RECIST 1.1
次要结局
- Safety will be assessed using NCI CTC-AE v5
- Efficacy will be documented using RECIST 1.1.
研究者
Patricia PAUTIER
Scientific
Asso De Recherche Cancers Gynecologiques
研究点 (13)
Loading locations...
相似试验
已完成
2 期
Phase 2 study of pembrolizumab and chemotherapy in participants with classical Hodgkin Lymphoma that has just been diagnosed2022-501615-14-00Merck Sharp & Dohme LLC50
招募中
2 期
Pembrolizumab in locally advanced sinonasal carcinoma - NeoPeSino2023-505917-25-00Istituti Clinici Scientifici Maugeri In Forma Abbreviata Istituti Clinici Scientifici Maugeri O Anche Ics Maugeri O Maugeri S.p.A. Sb28
招募中
2 期
A Phase 2 Study of MORAb-202 in Platinum-resistant High-grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancer2023-504111-33-00Bristol Myers Squibb International Corporation55
招募中
2 期
Phase II, open label, single arm study of PembrolizumAb combiNeD with cisplatin or carbOplatin and etoposide in treatment naïve advanced meRkel cell cArcinoma (MCC) (PANDORA Trial).2022-500988-12-00Fondazione IRCCS Istituto Nazionale Dei Tumori35
招募中
2 期
Study of chemotherapy and immunotherapy for patients with lung cancer bounded in the thorax and potentially resectable2024-513731-24-00Fundacion GECP90